NAGE
Niagen Bioscience Inc · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -13.3% ·
share flow -0.1% ·
net new positions -15.4%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 66 | -4 | 22.69M | $72.48M | +5 | −9 |
| Q1 2026 | 72 | -9 | 26.61M | $117.87M | +3 | −12 |
| Q4 2025 | 81 | 0 | 27.14M | $172.59M | +1 | −1 |
| Q3 2025 | 17 | +1 | 16.56M | $154.47M | +2 | −1 |
| Q2 2025 | 13 | -2 | 14.28M | $205.83M | — | −2 |
| Q1 2025 | 12 | +1 | 6.49M | $44.82M | +1 | — |
| Q4 2024 | 11 | +2 | 5.06M | $26.83M | +2 | — |
| Q3 2024 | 8 | +1 | 2.02M | $7.36M | +3 | −2 |
| Q2 2024 | 7 | — | 2.06M | $5.62M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 3.92M | — | $56.55M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 2 | BlackRock ✦ (passive) | 3.86M | — | $55.57M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 3 | D. E. Shaw & Co. ✦ | 1.60M | +24.8% | $23.08M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 1.30M | +9.9% | $18.67M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 5 | Arrowstreet Capital ✦ | 1.12M | +13.1% | $16.13M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | State Street Global Advisors ✦ (passive) | 1.02M | +10.0% | $14.70M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | AQR Capital Management ✦ | 491.61K | +39.6% | $7.08M | 0.0% | ▲ Add | 4 | SEC ↗ ×5 |
| 8 | Renaissance Technologies ✦ | 489.60K | -6.4% | $7.06M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 9 | Marshall Wace ✦ | 162.13K | -45.8% | $2.34M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 10 | GAMCO Investors ✦ | 128.80K | -9.8% | $1.86M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 11 | Millennium Management ✦ | 121.55K | -79.8% | $1.75M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | T. Rowe Price ✦ | 54.74K | +6.9% | $789,000 | 0.0% | ▲ Add | 5 | SEC ↗ |
| 13 | Fidelity (FMR) ✦ | 17.69K | — | $254,934 | 0.0% | n/c | 1 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Citadel Advisors | $737,603 | was 0.0% |
| Two Sigma Investments | $264,912 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 142 holders, 36.40M shares, $156.67M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.